NSE IPO - Apply Online, Check Issue Date, Price, Lot Size & Allotment Status

Apply for NSE IPO:

Skip to main content

Live Akebia Therapeutics, Inc. Share Price Chart

O H L

Akebia Therapeutics, Inc. Performance Overview

Days Range
$0.88Low
$0.91High

Markets Today

Previous Close$0.90
Open$0.89
Volume786,076
Day's Range$0.88 - $0.91
52W Range$0.81 - $3.20
Market Cap$254.33 M

Historical Performance

1M Returns+5.13
3M Returns-16.31
6M Returns-37.81
1Y Returns-69.75
5Y Returns-69.12
10Y Returns-90.12

Akebia Therapeutics, Inc. Fundamentals

Market Cap$254.33 M
Dividend yield0.00
PE Ratio0.00
PEG RatioN/A
Revenue$236.20 M
ROE TTMN/A
EPS TTM$-0.11
Quarterly Earnings Growth YOYN/A
PB Ratio9.97
EBITDA$24.77 M
Profit Margin-2.26
Market Cap$254.33 M
Dividend yield0.00
PE Ratio0.00
PEG RatioN/A
Revenue$236.20 M
ROE TTMN/A
EPS TTM$-0.11
Quarterly Earnings Growth YOYN/A
PB Ratio9.97
EBITDA$24.77 M
Profit Margin-2.26

Akebia Therapeutics, Inc. Profit & Loss

Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Total Revenue +$57.34 M$62.47 M$58.77 M$57.62 M$53.54 M$49.13 M
Gross Profit +$49.71 M$52.55 M$49.38 M$45.09 M$41.25 M$38.70 M
Operating Income $13.51 M$14.09 M$4.45 M-$8.55 M-$4.70 M-$6.33 M
EBITDA $13.83 M$14.40 M$4.77 M-$8.23 M-$4.37 M-$3.80 M
Interest Expense $0-$6.83 M$0$0$0-$3.07 M
Depreciation $314.00 K$316.00 K$318.00 K$321.00 K$328.00 K$2.53 M
Income Before Tax $6.11 M$247.00 K$1.16 M-$11.23 M-$8.93 M-$8.84 M
Income Tax Expense $0$0$615.00 K$1.01 M$126.00 K$70.00 K
Net Income +$6.11 M$247.00 K$540.00 K-$12.24 M-$9.05 M-$8.91 M
Net Profit Margin 10.66%0.4%0.92%-21.25%-16.91%-18.13%

Akebia Therapeutics, Inc. Financials Balance Sheet In USD

Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Share Capital $2.00 K$2.00 K$2.00 K$2.00 K$2.00 K$2.00 K
Reserve & Surplus -$1.67 B-$1.67 B-$1.67 B-$1.68 B-$1.69 B-$1.70 B
Non-Current Liabilities $194.38 M$197.65 M$189.18 M$181.02 M$161.26 M$163.78 M
Current Liabilities $91.23 M$118.72 M$133.38 M$162.94 M$173.88 M$160.87 M
Total Liabilities $285.60 M$316.37 M$322.56 M$343.95 M$335.14 M$324.64 M
Fixed Assets $1.90 M$1.71 M$1.47 M$1.22 M$956.00 K$1.51 M
Current Assets $203.78 M$234.66 M$258.34 M$252.96 M$243.48 M$229.55 M
Total Assets $310.19 M$345.60 M$364.15 M$376.56 M$362.52 M$349.66 M

Akebia Therapeutics, Inc. Cash Flow

Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Net Income $6.11 M$247.00 K$540.00 K-$12.24 M-$9.05 M-$8.91 M
Operating Cash Flow -$13.59 M$22.34 M$28.11 M$31.13 M-$21.21 M$3.52 M
Investing Cash Flow $154.00 K-$126.00 K-$77.00 K-$7.88 M-$62.00 K-$4.08 M
Financing Cash Flow $74.94 M$1.72 M$1.11 M-$4.85 M-$926.00 K-$6.54 M
Change in Cash $61.51 M$23.94 M$29.14 M$18.40 M-$22.20 M-$7.09 M

Akebia Therapeutics, Inc. Return Calculator

The Akebia Therapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Returns Estimator

Based on past performance of this fund

ENTER AMOUNT
$10,000
Select Duration
5Yrs
1 Yr5 Yrs
If you had invested $10,000 5 years ago, what would its value be today?$3,000
Invested Amount$10,000
Est. Returns$-7,000
Invest in USA Stock Today

About Akebia Therapeutics, Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

FAQs

Akebia Therapeutics, Inc. (AKBA) share price as of September 18, 2026 is $0.87. If you are investing from India, you can always check the valuation in the INR before investing.
Yes, Indian Investors can invest in the Akebia Therapeutics, Inc. (AKBA) Share by opening an international trading account with Angel One.
Purchasing Akebia Therapeutics, Inc. (AKBA) share from India can be done by: Directly: By opening an international trading account with Angel One. The process would include KYC verification. The account activation takes a few minutes to a few hours, after which you can start buying Akebia Therapeutics, Inc. (AKBA) by making deposits in US dollars. Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.
Yes, you can purchase fractional shares of Akebia Therapeutics, Inc. (AKBA) or any other US company shares in Angel One for any dollar amount.
The market capitalization of Akebia Therapeutics, Inc. on September 18, 2026, is $254.33 M.
Akebia Therapeutics, Inc. operates in the Healthcare sector, specifically in the Healthcare industry.
In order to invest in Akebia Therapeutics, Inc. (AKBA) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.). From start to end, the process is digital and can be seamless.

Diversify Your Portfolio with US Stocks

Invest in Wall Street Giants from India

+91
Top US Stocks

VIEW ALL

Open Free Demat Account!

Join our 3.8 Cr+ happy customers
+91